Oncolytics Biotech® to Host Conference Call to Discuss Second Quarter Financial Results and Recent Operational Highlights
Rhea-AI Summary
Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapy company focused on oncology, has announced a conference call and webcast scheduled for Thursday, August 1, 2024, at 4:30 p.m. ET. The event will provide a corporate update and discuss financial results for the second quarter of 2024. Investors and interested parties can join via North American toll-free number (800) 836-8184 or international number (646) 357-8785, using conference ID 34386. A webcast will also be available on the company's Investor Relations page and archived for three months. A dial-in replay will be accessible for one week after the call.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, ONCY gained 0.98%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Conference call and webcast to take place on Thursday, August 1, 2024, at 4:30 p.m. ET
Conference Call & Webcast
Date: Thursday, August 1, 2024
Time: 4:30 p.m. ET
Dial In – North American Toll-Free: (800) 836-8184
Dial In – International: (646) 357-8785
RapidConnect: to join the conference call without operator assistance, please click here
Conference ID (if needed): 34386
Webcast: please click here
A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA. For further information, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Company Contact Jon Patton Director of IR & Communication | Investor Relations for Oncolytics Timothy McCarthy LifeSci Advisors +1-917-679-9282 |
View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-second-quarter-financial-results-and-recent-operational-highlights-302204603.html
SOURCE Oncolytics Biotech® Inc.
FAQ
When is Oncolytics Biotech (ONCY) hosting its Q2 2024 earnings call?
How can investors access Oncolytics Biotech's (ONCY) Q2 2024 earnings call?
What will be discussed in Oncolytics Biotech's (ONCY) upcoming conference call?
How long will the replay of Oncolytics Biotech's (ONCY) Q2 2024 earnings call be available?
